Jared Castle

Dr. Jared Castle


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2024 in Clinical Toxicology
Verified
Journal Article
Closed access
RSRebekka Syrjanen
Rebekka Syrjanen
JSJennifer Schumann
Jennifer Schumann
JCJared Castle
Jared Castle
LSLesley Sharp
Lesley Sharp
AGAndrew Griffiths
Andrew Griffiths
SGShaun L. Greene
Shaun L. Greene
Protonitazene is an opioid belonging to the 2-benzylbenzimidazole structural class. We describe two cases of opioid toxicity involving the reported inhalation of a delta-9-tetrahydrocannabinol vape product in which protonitazene was detected. Case 1 was a young male found unconscious after the reported use of a delta-9-tetrahydrocannabinol vape. He suffered two subsequent apnoeic episodes requiring bag-valve-mask ventilation before eventual recovery. Only protonitazene was detected in blood at a concentration of 0.74 µg/L. Case 2 was a young male who died shortly after being found unresponsive. The postmortem femoral blood concentrations of protonitazene and delta-9-tetrahydrocannabinol were 0.33 µg/L and 2 µg/L, respectively. Analysis of a pod vaping device found in the decedent's hand and a separate e-liquid bottle labelled as delta-9-tetrahydrocannabinol showed a mixture of protonitazene and delta-9-tetrahydrocannabinol. The opioid effects of protonitazene are mediated through β-arrestin2 and mu opioid receptor signalling pathways. Benzimidazole opioids are lipophilic and, when mixed with a suitable solvent, can be used in a vape device. It is anticipated that naloxone would have provided effective reversal of toxicity in our cases. Novel routes of opioid administration, like vaping, may appear relatively innocuous in comparison to intravenous administration, but opioids may still be absorbed at high concentrations, resulting in severe opioid toxicity or death.

27 August 2024 in Journal of Analytical Toxicology
Verified
Journal Article
Closed access
PDF file
ODOlaf H Drummer
Olaf H Drummer
SJSamantha Joubert
Samantha Joubert
MRMatthew Di Rago
Matthew Di Rago
JCJared Castle
Jared Castle
KCKerryn Crump
Kerryn Crump
DGDimitri Gerostamoulos
Dimitri Gerostamoulos
Novel benzodiazepine (NBz) detections in Victorian coronial cases started early in 2018 and have continued to increase in number and type up to December 2022. The 11 different NBz detections included etizolam (n = 82), flualprazolam (n = 43), clonazolam or 8-aminoclonazolam (n = 30), bromazolam (n = 15), clobromazolam (n = 13), phenazepam (n = 13), flubromazolam (n = 12), flubromazepam (n = 8), desalkylflurazepam (n = 6), diclazepam (n = 2), and estazolam (n = 1). The pattern of detections varied over the 5-year period, with different compounds appearing over different time frames. The most recent NBz to appear were bromazolam, clobromazolam, flubromazepam, and phenazepam, whereas etizolam had been seen regularly in case work since 2018. Of the total 133 deaths, 95 were considered drug-related deaths by forensic pathologists with at least one additional CNS depressant also present capable of contributing to death. All deaths involved other (non-benzodiazepine) CNS active drugs, although many involved multiple NBz, with five or more different benzodiazepines detected in eight cases.

29 March 2023 in Clinical Toxicology
Verified
Journal Article
Open access
RSRebekka Syrjanen
Rebekka Syrjanen
SGShaun L. Greene
Shaun L. Greene
JCJared Castle
Jared Castle
MRMatthew Di Rago
Matthew Di Rago
SHSarah E. Hodgson
Sarah E. Hodgson
JSJennifer Schumann
Jennifer Schumann
Clonazolam is an unregistered novel benzodiazepine which emerged in global illicit drug markets in 2014. We describe the clinical features of four cases of non-fatal clonazolam mono-intoxications f...

23 February 2024 in Journal of Analytical Toxicology
Verified
Journal Article
Closed access
PDF file
JCJared Castle
Jared Castle
RSRebekka Syrjanen
Rebekka Syrjanen
MRMatthew Di Rago
Matthew Di Rago
JSJennifer Schumann
Jennifer Schumann
SGShaun L Greene
Shaun L Greene
DGDimitri Gerostamoulos
Dimitri Gerostamoulos
The proliferation of novel psychoactive substances (NPSs) continues to challenge toxicology laboratories. In particular, the United Nations Office on Drugs and Crime considers designer benzodiazepines to be a current primary threat among all NPSs. Herein, we report detection of a new emerging designer benzodiazepine, clobromazolam, using high-resolution mass spectrometry and untargeted data acquisition in combination with a “suspect screening” method built from the crowd-sourced HighResNPS.com database. Our laboratory first detected clobromazolam in emergency department presenting intoxications included within the Emerging Drugs Network of Australia—Victoria project in the state of Victoria, Australia, from April 2022 to March 2023. Clobromazolam was the most frequent designer benzodiazepine detected in this cohort (100/993 cases, 10%). No patients reported intentional administration of clobromazolam, although over half reported exposure to alprazolam, which was detected in only 7% of cases. Polydrug use was prevalent (98%), with phenazepam (45%), methylamphetamine (71%) and other benzodiazepines (60%) most frequently co-detected. This is the first case series published in the literature concerning clobromazolam in clinical patients. The identification of clobromazolam in patients presenting to emergency departments in Victoria demonstrates how high-resolution mass spectrometry coupled with the HighResNPS.com database can be a valuable tool to assist toxicology laboratories in keeping abreast of emerging psychoactive drug use.

15 February 2022 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
JCJared Castle
Jared Castle
DBDanielle M. Butzbach
Danielle M. Butzbach
FRFrank Reith
Frank Reith
GWGeorge Stewart Walker
George Stewart Walker
CLClaire E. Lenehan
Claire E. Lenehan
KKK. Paul Kirkbride
K. Paul Kirkbride

1 May 2023 in Drug Testing and Analysis
Verified
Journal Article
Open access
JCJared Castle
Jared Castle
DBDanielle M. Butzbach
Danielle M. Butzbach
GWGeorge Stewart Walker
George Stewart Walker
CLClaire E. Lenehan
Claire E. Lenehan
FRFrank Reith
Frank Reith
KKK. Paul Kirkbride
K. Paul Kirkbride
Recent research reported that lurasidone degrades in unpreserved ante-mortem human whole blood inoculated with microorganisms known to dominate postmortem blood specimens. In vitro degradation occurred at a similar rate to risperidone, known to degrade in authentic postmortem specimens until below analytical detection limits. To identify the lurasidone degradation products formed, an Agilent 6520 liquid chromatograph quadrupole-time-of-flight mass spectrometer (LC-QTOF-MS) operating in auto-MS/MS mode was used. Numerous degradation products not previously reported in prior in vitro or in vivo pharmacokinetic studies or forced degradation studies were detected. Accurate mass data, mass fragmentation data, acetylation experiments, and a proposed mechanism of degradation analogous to risperidone supports initial identification of the major degradation product as N-debenzisothiazole-lurasidone (calculated m/z [M + H](+) = 360.2646). A standard was unavailable to conclusively confirm this identification. Retrospective data analysis of postmortem cases involving lurasidone identified the presence of the major degradation product in four of six cases where lurasidone was also detected. This finding is significant for toxicology laboratories screening for this drug in postmortem casework. The major postmortem lurasidone degradation product has consequently been added to the LC-QTOF-MS drug screen at Forensic Science SA (FSSA) to indicate postmortem lurasidone degradation in authentic postmortem blood specimens and as a marker of lurasidone administration in the event lurasidone is degraded to concentrations below detection limits.